Hunting Hill Global Capital’s Abivax ABVX Stock Holding History

Hunting Hill Global Capital’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,775	Closed	-$309K	–	2
2026 Q1	$309K	Buy	+2,775	New	+$328K	0.24%	57

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hunting Hill Global Capital's ABVX Position: Q2 2026 in Review

Hunting Hill Global Capital sold out of Abivax (ABVX) in Q2 2026, closing a stake of 2,775 shares — an estimated $309K sold.

Hunting Hill Global Capital first reported a position in ABVX in Q1 2026 and held it in 1 quarter. The position peaked at $309K in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Hunting Hill Global Capital reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
Hunting Hill Global Capital sold 2,775 Abivax shares in Q2 2026, an estimated $309K.
Hunting Hill Global Capital first reported a position in Abivax in Q1 2026 and held it in 1 quarter.
Hunting Hill Global Capital's Abivax position peaked at $309K in Q1 2026.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Hunting Hill Global Capital's 13F filing for Q2 2026.